9,589 results match your criteria Psoriatic Arthritis


Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.

Dig Liver Dis 2019 Apr 13. Epub 2019 Apr 13.

IBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy. Electronic address:

Background: Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis.

Aims: to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription.

Methods: This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dld.2019.03.007DOI Listing

Research of Pathogenesis and Novel Therapeutics in Arthritis.

Authors:
Chih-Hsin Tang

Int J Mol Sci 2019 Apr 2;20(7). Epub 2019 Apr 2.

Department of Pharmacology, School of Medicine, China Medical University, Taichung 40402, Taiwan.

Arthritis has a high prevalence globally and includes over 100 types, the most common of which are rheumatoid arthritis, osteoarthritis, psoriatic arthritis and inflammatory arthritis. The exact etiology of arthritis remains unclear and no cure exists. Anti-inflammatory drugs are commonly used in the treatment of arthritis, but are associated with significant side effects. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/1422-0067/20/7/1646
Publisher Site
http://dx.doi.org/10.3390/ijms20071646DOI Listing
April 2019
1 Read

Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open label one year study.

J Dermatolog Treat 2019 Apr 15:1-17. Epub 2019 Apr 15.

a Centre for the Study and Treatment of Psoriasis at the Department of Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS , Via Elio Chianesi 53 , 00144 Rome , Italy.

Background: Currently, there are no studies specifically aimed at investigating the effectiveness of etanercept biosimilar SB4 in psoriatic arthritis (PsA).

Objectives: Our primary objective was to verify the ability of SB4 to maintain low disease activity in patients switching to SB4 after 1 year of treatment with the reference etanercept.

Methods: Eighty-seven PsA patients with low disease activity at baseline measured by using the clinical Disease Activity Index for Psoriatic Arthritis ≤13 (cDAPSA; range 0-154) were prospectively evaluated after 6 and 12 months when switching from the reference etanercept to SB4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1606886DOI Listing

Editorial: Immunology of Psoriatic Disease.

Front Immunol 2019 29;10:657. Epub 2019 Mar 29.

Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449451PMC

Alopecia areata is characterised by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity.

Br J Dermatol 2019 Apr 13. Epub 2019 Apr 13.

Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.

Background: Alopecia areata (AA) is a common autoimmune disease, causing patchy hair loss that can progress to involve the entire scalp (totalis) or body (universalis). CD8 NKG2D T cells dominate hair follicle pathogenesis, but the specific mechanisms driving hair loss are not fully understood.

Objectives: To provide a detailed insight into the systemic cytokine signature associated with AA, and assess the association between cytokines and depression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.18008DOI Listing

PAPASH, PsAPASH and PASS autoinflammatory syndromes: Phenotypic heterogeneity, common biological signature and response to immunosuppressive regimens.

Br J Dermatol 2019 Apr 13. Epub 2019 Apr 13.

Department of Dermatology, APHP Hôpital St-Louis, Paris.

Hidradenitis suppurativa (HS) is a chronic inflammatory disease of skin appendages, commonly associating with other conditions including spondyloarthritis, and is a major component of severe cutaneo-articular autoinflammatory syndromes (AIS), called PAPASH (Pyogenic Arthritis, pyoderma gangrenosum/PG, Acne, HS), PsAPASH (Psoriatic Arthritis, PG, Acne, HS) and PASS (Ankylosing Spondylitis, Acne, PG and HS). The clinical phenotypes of these AIS are ill-defined and unlike PASH or PAPA syndromes, still lack any biological or genetic marker. Moreover, their optimal therapeutic management remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.18003DOI Listing

Efficacy and Safety of Intravenous Golimumab through 1 Year in Patients with Active Psoriatic Arthritis.

Arthritis Care Res (Hoboken) 2019 Apr 12. Epub 2019 Apr 12.

Janssen Research & Development, LLC, Spring House, PA, USA.

Objective: Evaluate safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis (PsA) through 1 year.

Methods: GO-VIBRANT was a Phase 3, randomized, placebo-controlled trial of 480 adults with active PsA. Patients were randomized to intravenous placebo (n=239) or golimumab 2 mg/kg (n=241) at weeks 0, 4, 12, and 20, with placebo crossover to golimumab at weeks 24, 28, and q8w. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23905DOI Listing

Score tests based on a finite mixture model of Markov processes under intermittent observation.

Stat Med 2019 Apr 10. Epub 2019 Apr 10.

Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada.

A mixture model is described, which accommodates different Markov processes governing disease progression in a finite set of latent classes. We give special attention to the setting in which individuals are examined intermittently and transition times are consequently interval censored. A score test is developed to identify genetic markers associated with class membership. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.8155
Publisher Site
http://dx.doi.org/10.1002/sim.8155DOI Listing
April 2019
1 Read

Development of clinical diagnostic criteria for plaque psoriasis in children: An eDelphi consensus study with the International Psoriasis Council.

Br J Dermatol 2019 Apr 10. Epub 2019 Apr 10.

Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.

Psoriasis in children can be a challenging diagnosis: the clinical presentation is often more subtle, may occur in covered sites and can be an unexpected diagnosis as psoriasis if often thought to occur at older ages. Poor recognition and delayed diagnosis of psoriasis in children can lead to inadequate treatment and lack of monitoring for comorbidities including juvenile psoriatic arthritis. Diagnostic criteria would help both clinical practice and clinical research, but to date none are available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17994DOI Listing

Antagonizing Retinoic Acid-Related-Orphan Receptor Gamma Activity Blocks the T Helper 17/Interleukin-17 Pathway Leading to Attenuated Pro-inflammatory Human Keratinocyte and Skin Responses.

Front Immunol 2019 26;10:577. Epub 2019 Mar 26.

Autoimmunity, Transplantation, and Inflammation Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland.

The nuclear hormone receptor retinoic acid receptor-related-orphan-receptor-gamma t (RORγt) is the key transcription factor required for Th17 cell differentiation and for production of IL-17 family cytokines by innate and adaptive immune cells. Dysregulated Th17 immune responses have been associated with the pathogenesis of several inflammatory and autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. In this article, we describe the pharmacology of a potent and selective low molecular weight RORγt inhibitor identified after a structure-based hit-to-lead optimization effort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00577DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443933PMC

Biologic therapy for acrodermatitis continua of Hallopeau: successful treatment with secukinumab and review of the literature.

Dermatol Ther 2019 Apr 10:e12899. Epub 2019 Apr 10.

Dermatology, Department of "Medicina dei Sistemi", University of Rome "Tor Vergata", Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12899DOI Listing

Successful treatment of psoriatic crumbly nails with ustekinumab.

Dermatol Ther 2019 Apr 9:e12914. Epub 2019 Apr 9.

Dermatology Unit, University of Rome "Tor Vergata", Rome, Italy.

Nail involvement can place a significant burden on patients as a result of functional damage and psychosocial problems, leading to major repercussions on the quality of life. There is strong evidence that nail psoriasis can often be difficult to treat. We report a a 69 year-old-man with severe onychodystrophy, onycholysis, and pain in the hands; he had been previously treated with topical and systemic traditional therapies without satisfactory response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12914DOI Listing

Hypersensitivity reaction to certolizumab pegol in a patient affected by psoriatic arthritis.

Dermatol Ther 2019 Apr 9:e12900. Epub 2019 Apr 9.

Department of Health Sciences, University of Catanzaro "Magna Graecia", Catanzaro, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12900DOI Listing

Safety and efficacy of Certolizumab Pegol in a real-life cohort of patients with Psoriasis and Psoriatic Arthritis.

J Dermatolog Treat 2019 Apr 9:1-20. Epub 2019 Apr 9.

d Dermatology Department, Department of Biotechnological and Applied Clinical Science , School of Medicine, University of L'Aquila , Italy.

Background: Aim of this observational study was to assess safety and efficacy of Certolizumab Pegol(CZP) in a real-life cohort of patients affected by psoriasis(PsO) and psoriatic arthritis(PsA), who had an inadequate response to previous systemic immunosuppressive treatments, with a follow-up of 24 weeks.

Materials And Methods: Twelve patients with PsO and PsA, referring to our Dermatology/Rheumatology combined outpatient clinic, were enrolled.Primary endpoints were safety and efficacy of CZP, defined as statistically significant improvement of DAPSA, clinical DAPSA and PASI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1605143DOI Listing

Systemic rheumatic diseases: From biological agents to small molecules.

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Rheumatology Unit, University of Messina, Messina, Italy.

The development of biologics and small oral molecules has recently changed the scenario of pharmacologic treatment of systemic rheumatic diseases and it has become a real revolution. These drugs have innovative mechanisms of action, based on the inhibition of specific molecular or cellular targets directly involved in disease pathogenesis. This new scenario has lead to a regular update of the management recommendations of several institututions, such as those for Rheumatoid Arthritis treatment that address the use of conventional and biologic therapies including TNFin (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, IL-6 inhibitors (tocilizumab and sarilumab), biosimilars and small oral molecules (the JAK inhibitors tofacitinib and baricitinib). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193008
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2018.12.009DOI Listing
April 2019
3 Reads

Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease.

Autoimmun Rev 2019 Apr 5. Epub 2019 Apr 5.

Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that may be present in near 30% of patients affected by psoriasis (PsO), clinically characterized by inflammation of periarticular (e.g., enthesis) and articular structures. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15689972193008
Publisher Site
http://dx.doi.org/10.1016/j.autrev.2018.11.007DOI Listing
April 2019
3 Reads

FEATURES OF MICROBIOTA IN PSORIATIC DISEASE: FROM SKIN AND GUT PERSPECTIVES (REVIEW).

Georgian Med News 2019 Feb(287):98-104

Republican Public Union "Kazakhstan Association of Human Microbiome Research", Nur-sultan (Astana), Kazakhstan.

Psoriatic disease is a chronic inflammatory disease characterized by skin lesions. Psoriasis development has been associated both with genetic and environmental factors. Though skin and gut microbiota has been implicated in number of pathologies including atopic dermatitis, inflammatory bowel disease, Crohn's disease, allergy, and obesity, its role has been poorly studied in psoriatic disease, which incorporates both psoriasis and psoriatic arthritis. Read More

View Article

Download full-text PDF

Source
February 2019

Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib.

Proc (Bayl Univ Med Cent) 2018 Oct 21;31(4):524-525. Epub 2018 Sep 21.

Department of Dermatology, Baylor University Medical CenterDallasTexas.

We report the first case of atopic dermatitis successfully treated with the oral Janus kinase-1 (JAK1) inhibitor oclacitinib. A man in his 70s, with a 6-year history of skin disease refractory to topical and biologic therapies, self-prescribed this veterinary medication with rapid remission of symptoms. He has remained in remission for 7 months with no reported adverse side effects or infections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08998280.2018.1480246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413965PMC
October 2018
1 Read

Faecal microbiota transplantation for Clostridium difficile infection resulting in a decrease in psoriatic arthritis disease activity.

Clin Exp Rheumatol 2019 Mar 27. Epub 2019 Mar 27.

Centre for Nutrition and Gastrointestinal Disease Research, The University of Adelaide and South Australian Health and Medical Research Institute, and Department of Gastroenterology, The Queen Elizabeth Hospital, Woodville, South Australia, Australia.

View Article

Download full-text PDF

Source
March 2019
2 Reads

Factors associated with patient-physician discordance in a prospective cohort of patients with psoriatic arthritis: An Asian perspective.

Int J Rheum Dis 2019 Apr 3. Epub 2019 Apr 3.

Department of Rheumatology & Immunology, Singapore General Hospital, Singapore City, Singapore.

Objectives: To evaluate factors associated with patient-physician discordance in a multiethnic Asian cohort of psoriatic arthritis (PsA) patients.

Methods: We used data from a prospective cohort of consecutive patients with PsA fulfilling the Classification Criteria for Psoriatic Arthritis, recruited from a single center in Singapore. Sociodemographic, clinical data and patient-reported outcomes were collected using a standardized protocol at baseline, 4 months, 8 months, 1 year, 2 years and 5 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13568DOI Listing
April 2019
1.771 Impact Factor

Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?

Clin Drug Investig 2019 Apr 2. Epub 2019 Apr 2.

Rheumatology Unit, Department of Emergency and Organ Transplantation, University of Bari, Pz. G. Cesare, 11, 70124, Bari, Italy.

Background: Identification of predictors of clinical response to certolizumab-pegol (certolizumab) may aid the decision-making process for treating patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA).

Objective: The aim of our study was to evaluate the effectiveness of certolizumab and identify any predictors of favorable outcome in patients with RA, PsA, or SpA.

Methods: We studied 355 RA, SpA, and PsA patients starting treatment with certolizumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40261-019-00782-9DOI Listing
April 2019
2 Reads

Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses.

Front Immunol 2019 19;10:382. Epub 2019 Mar 19.

Immunoregulation Unit, Department of Immunology, Institut Pasteur, Paris, France.

Immune-mediated inflammatory diseases (IMIDs), such as spondyloarthritis (SpA), psoriasis, Crohn's disease (CD), and rheumatoid arthritis (RA) remain challenging illnesses. They often strike at a young age and cause lifelong morbidity, representing a considerable burden for the affected individuals and society. Pioneering studies have revealed the presence of a TNF-dependent proinflammatory cytokine cascade in several IMIDs, and the introduction of anti-TNF therapy 20 years ago has proven effective to reduce inflammation and clinical symptoms in RA, SpA, and other IMID, providing unprecedented clinical benefits and a valid alternative in case of failure or intolerable adverse effects of conventional disease-modifying antirheumatic drugs (DMARDs, for RA) or non-steroidal anti-inflammatory drugs (NSAIDs, for SpA). Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2019.00382
Publisher Site
http://dx.doi.org/10.3389/fimmu.2019.00382DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434926PMC
March 2019
2 Reads

Small Molecule and Pooled CRISPR Screens Investigating IL17 Signaling Identify BRD2 as a Novel Contributor to Keratinocyte Inflammatory Responses.

ACS Chem Biol 2019 Apr 15. Epub 2019 Apr 15.

Discovery Dermatology & Fibrosis , AbbVie Bioresearch Center , Worcester , Massachusetts 01605 , United States.

Interleukin-17A (IL17A) plays a critical role in the development of numerous autoimmune diseases, including psoriasis. The clinical success of IL17A neutralizing biologics in psoriasis has underlined its importance as a drug discovery target. While many studies have focused on the differentiation and trafficking of IL17A producing T-helper 17 cells, less is known about IL17A-initiated signaling events in stromal and parenchymal cells leading to psoriatic phenotypes. Read More

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/acschembio.8b00260
Publisher Site
http://dx.doi.org/10.1021/acschembio.8b00260DOI Listing
April 2019
3 Reads

Data linkages between patient-powered research networks and health plans: a foundation for collaborative research.

J Am Med Inform Assoc 2019 Apr 2. Epub 2019 Apr 2.

HealthCore, Wilmington, Delaware, USA.

Objective: Patient-powered research networks (PPRNs) are a valuable source of patient-generated information. Diagnosis code-based algorithms developed by PPRNs can be used to query health plans' claims data to identify patients for research opportunities. Our objective was to implement privacy-preserving record linkage processes between PPRN members' and health plan enrollees' data, compare linked and nonlinked members, and measure disease-specific confirmation rates for specific health conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jamia/ocz012DOI Listing
April 2019
3.504 Impact Factor

Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based case control study.

Clin Rheumatol 2019 Apr 1. Epub 2019 Apr 1.

Rheumatology Unit, Carmel Medical Center, 7 Michal Street, 34362, Haifa, Israel.

Objective: To assess the prevalence of risk factors associated with cardiovascular disease (CVD) and CVD-related morbidity in a large Middle-Eastern psoriatic arthritis (PsA) cohort.

Method: A retrospective case control study was conducted using Israel's largest health care provider's patient database from 2000 to 2013. For each patient with PsA, 10 patients with no history of psoriasis or arthritis were matched for age and sex. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-019-04528-yDOI Listing
April 2019
2 Reads

[Gastrointestinal side effects of apremilast : Characterization and management].

Hautarzt 2019 Apr 1. Epub 2019 Apr 1.

Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland.

Apremilast is an oral inhibitor of phosphodiesterase-4 (PDE4) that is licensed for the second-line treatment of psoriasis and psoriatic arthritis. Data from several phase III clinical trials and real-world studies showed a good benefit-risk profile, with diarrhea and nausea as the most common adverse events. Diarrhea and nausea most frequently occurred during the first month of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00105-019-4396-6DOI Listing

Association between enthesitis and health-related quality of life in psoriatic arthritis in anti-TNF-naïve patients from two Phase 3 ustekinumab trials.

J Rheumatol 2019 Apr 1. Epub 2019 Apr 1.

From the University of Glasgow, Institute of Infection Immunity & Inflammation, Glasgow Biomedical Research Centre, Glasgow, Scotland; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Dermatology, Icahn School of Medicine at Mt Sinai, New York, NY; University of Rochester, Medical Center, Rochester, NY; Janssen Research & Development, LLC., Spring House, PA; Janssen Scientific Affairs, LLC, Horsham, PA; Memorial University, NL, Canada; University of California-San Diego, CA. This study was funded by Janssen Research & Development, LLC. Address correspondence to Iain McInnes, Institute of Infection Immunity & Inflammation, Glasgow Biomedical Research Centre, Level 4, 120 University Place, Glasgow, Scotland, G12 8TA, United Kingdom. E-mail:

Objective: Evaluate enthesitis, physical function, and HRQoL among anti-TNF-naïve PsA patients.

Methods: In PSUMMIT 1 and 2, PsA patients were randomized to placebo or ustekinumab 45mg or 90mg. Enthesitis was assessed at weeks 0 and 24 (MASES). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180792DOI Listing
April 2019
1 Read

Exploring Dimensions of Stiffness in Rheumatoid and Psoriatic Arthritis: The ARAD and OMERACT Stiffness Special Interest Group collaboration.

J Rheumatol 2019 Apr 1. Epub 2019 Apr 1.

From the Institute of Bone and Joint Research, Kolling Institute, St Leonards, NSW Australia; Rheumatology Department, Royal North Shore Hospital, St Leonards, NSW Australia; Sydney Medical School, University of Sydney, Sydney, NSW Australia; Divisions of Clinical Epidemiology, Rheumatology, and Respiratory Epidemiology, McGill University, Montreal Canada; Division of Rheumatology, Johns Hopkins Medicine, Baltimore USA; Department of Nursing and Midwifery, University of the West of the England, Bristol, United Kingdom; Monash Department of Clinical Epidemiology, Cabrini Institute, Melbourne, Victoria, Australia; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, SA Australia; Discipline of Medicine, University of Adelaide, South Australia;1 School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW Australia; Rheumatology Department, St George Hospital, Kogarah, NSW Australia. The Australian Rheumatology Association Database is currently supported by unrestricted educational grants administered through the Australian Rheumatology Association from AbbVie Pty Ltd, Pfizer Australia, Sanofi Australia, Celgene Australian & NZ, Bristol-Myers Squibb Australia Pty Ltd. Previous sponsorship for ARAD included an Australian National Health and Medical Research Council (NHMRC) Enabling Grant [384330], Amgen Australia Pty Ltd, Aventis, AstraZeneca, Roche, Monash University, Cabrini Health. Infrastructure support for ARAD received from Cabrini Hospital, Royal North Shore Hospital and the Australian Rheumatology Association. P. Sinnathurai is supported by an NHMRC Postgraduate Scholarship. R. Buchbinder is funded by an NHMRC Senior Principal Research Fellowship. Address correspondence to Premarani Sinnathurai, Rheumatology Department, Royal North Shore Hospital, Reserve Road, St Leonards NSW 2125 AUSTRALIA.

Objective: It is not known how the experience of stiffness varies between diagnoses or how best to measure stiffness. The aims of this study were to: 1) compare stiffness in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) using patient-reported outcomes, 2) explore how dimensions of stiffness are associated with each other and reflect the patient experience, 3) explore how different dimensions of stiffness are associated with physical function.

Methods: An online survey was sent to Australian Rheumatology Association Database participants (158 PsA, and 158 age- and sex-matched RA), assessing stiffness severity, duration, impact, importance, coping and physical function (mHAQ). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181251DOI Listing
April 2019
1 Read

Acrodermatitis Continua of Hallopeau with Psoriatic Arthritis.

J Rheumatol 2019 Apr;46(4):437-438

Department of Dermatology and Skin Science, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180086DOI Listing

The Role of Ultrasound in Psoriatic Arthritis - Do We Need a Score?

J Rheumatol 2019 Apr;46(4):337-339

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181044DOI Listing
April 2019
1 Read

Off-label studies on apremilast in dermatology: a review.

J Dermatolog Treat 2019 Apr 2:1-10. Epub 2019 Apr 2.

a Division of Dermatology, Department of Medicine , David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.

Purpose: Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1589641DOI Listing
April 2019
4 Reads

Incidental papillary thyroid cancer diagnosis in patient with adult-onset Still's disease-like manifestations.

Authors:
R Tirri D Capocotta

Reumatismo 2019 Apr 1;71(1):42-45. Epub 2019 Apr 1.

Unit of Rheumatology, Department of Clinical and Sperimental Internal Medicine, Luigi Vanvitelli University, Napoli.

Adult onset Still's disease (AOSD) is a systemic inflammatory disease characterized primarily by a triad consisting of daily fever, arthritis and maculopapular exanthema. The pathogenesis and etiology of AOSD are unknown and the diagnosis, which can be very challenging, is often made by exclusion. Here, we report a case of a 61-year-old woman with a history of mild psoriatic arthritis, fever, arthritis and maculopapular exanthema. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/reumatismo.2019.1118DOI Listing
April 2019
1 Read

Impact of red meat, processed meat and fibre intake on risk of late-onset chronic inflammatory diseases: prospective cohort study on lifestyle factors using the Danish 'Diet, Cancer and Health' cohort (PROCID-DCH): .

BMJ Open 2019 Mar 30;9(3):e024555. Epub 2019 Mar 30.

Focused Research Unit for Molecular Diagnostic and Clinical Research, Hospital of Southern Jutland, Aabenraa, Denmark.

Introduction: Chronic inflammatory diseases (CIDs) (Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, rheumatoid arthritis and multiple sclerosis) are diseases of the immune system that have some shared genetic and environmental predisposing factors, but still few studies have investigated the effects of lifestyle on disease risk of several CIDs. The primary aim of this prospective cohort study is to investigate the impact of fibre, red meat and processed meat on risk of late-onset CID, with the perspective that results of this study can contribute in supporting future diet recommendations for effective personalised prevention.

Methods And Analysis: The study will use data from 57 053 persons from the prospective Danish cohort study 'Diet, Cancer and Health' together with National Health Registry data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2018-024555DOI Listing
March 2019
1 Read

Psoriasis and male sexuality.

Ann Dermatol Venereol 2019 Mar 27. Epub 2019 Mar 27.

Dermatology Department, hôpital Saint-André, CHU de Bordeaux, 33000 Bordeaux, France; Psoriasis Research Group (GrPso), société française de dermatologie, 75009 Paris, France.

Since sexual satisfaction is a key factor in quality-of-life scores, the aim of this review article is to examine current knowledge concerning the impact on male sexuality of psoriasis, particularly genital psoriasis. Risk factors for sexual dysfunction, and more specifically erectile dysfunction, demonstrated to date include severity of psoriasis, genital psoriasis, psoriatic arthritis, smoking, psychological disorders (anxiety-depression), cardiovascular comorbidities and side effects of psoriasis treatments. Studies evaluating the burden of genital psoriasis on male sexuality are contradictory: while the link between genital psoriasis and global sexual functioning has been clearly established in relation to question 9 of the DLQI, discrepancies exist between the scoring systems used concerning sexual satisfaction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2019.01.021DOI Listing
March 2019
2 Reads

Patients' perspectives and experience of psoriasis and psoriatic arthritis: a systematic review and thematic synthesis of qualitative studies.

Arthritis Care Res (Hoboken) 2019 Mar 30. Epub 2019 Mar 30.

Sydney School of Public Health, The University of Sydney, Sydney, Australia.

Objective: To describe the range and depth of perspectives and experiences of patients with psoriasis and psoriatic arthritis to inform gaps in patient centred care.

Methods: MEDLINE, Embase, PsycINFO, CINAHL were searched to April 2018. Thematic synthesis was used to analyse the findings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23896DOI Listing

Hypertension is associated with increased age at the onset of psoriasis and a higher body mass index in psoriatic disease.

Clin Rheumatol 2019 Mar 28. Epub 2019 Mar 28.

Dermatology Division, Hospital Alvarez Buylla, Mieres, Asturias, Spain.

Background And Aims: High blood pressure (HBP) is a common comorbidity in psoriatic disease. Some studies indicate a higher prevalence of HBP among arthritis patients, in relation to psoriasis alone, within the psoriatic spectrum. Our objective was to study the prevalence of HBP in both types of patients as well as to analyse the factors associated with it. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10067-019-04519-z
Publisher Site
http://dx.doi.org/10.1007/s10067-019-04519-zDOI Listing
March 2019
2 Reads

Consequences of bariatric surgery on outcomes in rheumatic diseases.

Arthritis Res Ther 2019 Mar 28;21(1):83. Epub 2019 Mar 28.

EA 4708 I3MTO Laboratory, University Orleans, 45067, Orleans, France.

Obesity is associated with numerous comorbidities including some rheumatic conditions. Through adipose-derived inflammation, obesity has been shown to induce increased initiation, progression, and worse responses on outcomes of rheumatic diseases. Bariatric surgery is being increasingly used thanks to its positive effects on major comorbidities such as type 2 diabetes mellitus and hypertension. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1869-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437847PMC
March 2019
2 Reads

Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.

Authors:
Lluís Puig

Expert Rev Clin Immunol 2019 Mar 28:1-9. Epub 2019 Mar 28.

a Department of Dermatology, Hospital de la Santa Creu i Sant Pau , Universitat Autònoma de Barcelona , Barcelona , Spain.

Introduction: Guselkumab is a subcutaneously administered monoclonal antibody that targets the IL-23p19 cytokine subunit and has been approved by the US FDA and the EMA for the treatment of moderate-to-severe psoriasis in adult patients. Areas covered: This review outlines the pharmacologic properties, efficacy and safety of guselkumab for the treatment of moderate-to-severe plaque psoriasis in adults. Expert opinion: In clinical trials, guselkumab markedly improved disease, regardless of topographical locations and patient subpopulations, with corresponding improvements in quality of life measures, and was generally well tolerated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1601014DOI Listing

Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.

JAMA Dermatol 2019 Mar 27. Epub 2019 Mar 27.

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Importance: Accumulating evidence indicates that there is an increased risk of cardiovascular disease among patients with psoriatic disease. Although an emerging concern that the risk of atrial fibrillation (AF) may also be higher in this patient population adds to the growing support of initiating early interventions to control systemic inflammation, evidence on the comparative cardiovascular safety of current biologic treatments remains limited.

Objective: To evaluate the risk of AF and major adverse cardiovascular events (MACE) associated with use of ustekinumab vs tumor necrosis factor inhibitors (TNFi) in patients with psoriasis or psoriatic arthritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2019.0001DOI Listing

Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial.

Rheumatol Ther 2019 Mar 27. Epub 2019 Mar 27.

US Medical, Amgen Inc., Thousand Oaks, CA, USA.

Introduction: Etanercept, a tumor necrosis factor inhibitor, is used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA), and is administered via subcutaneous injection. Injection site pain (ISP) associated with subcutaneous administration may affect compliance or hinder initiation of prescribed medications. To improve the patient experience, a new phosphate-free formulation of etanercept was evaluated for reduced ISP associated with administration. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40744-019-0152-8
Publisher Site
http://dx.doi.org/10.1007/s40744-019-0152-8DOI Listing
March 2019
3 Reads

Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay.

Sci Rep 2019 Mar 26;9(1):5211. Epub 2019 Mar 26.

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA.

Because development of reliable biomarkers in psoriasis and atopic dermatitis has lagged behind therapeutic progress, we created a blood-based test to fill the void in objective methods available for dermatological assessments. Our novel interleukin-19 (IL-19) immunoassay was initially tested to determine concentrations of IL-19 serum levels, then correlated with the psoriasis activity and severity index (PASI) in psoriasis, and the eczema area and severity index (EASI) in atopic dermatitis. Not only was IL-19 increased in psoriasis and correlated to PASI, but ixekizumab administration led to rapid, sustained IL-19 decreases to normal levels, with decreases at 2-weeks correlating with PASI improvement at 16-weeks. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-019-41609-z
Publisher Site
http://dx.doi.org/10.1038/s41598-019-41609-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435799PMC
March 2019
4 Reads

Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database.

J Comp Eff Res 2019 Mar 26. Epub 2019 Mar 26.

Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.

Aim: To evaluate the persistence and adherence of subcutaneous biologics in patients with psoriatic arthritis (PsA).

Patients & Methods: Psoriatic arthritis patients who initiated adalimumab, certolizumab pegol, etanercept, golimumab or secukinumab between 15 January 2016 and 31 July 2017 were identified in the Truven Databases. Outcomes included discontinuation rate, persistence and adherence over 12 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cer-2019-0023DOI Listing
March 2019
1 Read

Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis.

Ann Rheum Dis 2019 Mar 25. Epub 2019 Mar 25.

Division of Rheumatology, Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada

Objectives: We aimed to identify soluble biomarkers that differentiate psoriatic arthritis (PsA) from osteoarthritis (OA).

Methods: Markers of cartilage metabolism (cartilage oligomeric matrix protein [COMP], hyaluronan), metabolic syndrome (adiponectin, adipsin, resistin, hepatocyte growth factor [HGF], insulin, leptin) and inflammation (C-reactive protein [CRP], interleukin-1β [IL-1β], IL-6, IL-8, tumour necrosis factor alpha [TNFα], monocyte chemoattractant protein-1 [MCP-1], nerve growth factor [NGF]) were compared in serum samples from 201 patients with OA, 77 patients with PsA and 76 controls. Levels across the groups were compared using the Kruskal-Wallis test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214737DOI Listing
March 2019
1 Read

Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report.

J Clin Med 2019 Mar 22;8(3). Epub 2019 Mar 22.

Dipartimento di Reumatologia e Scienze Mediche, ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, 20122 Milano, Italy.

Psoriatic arthritis (PsA) is a chronic immune-mediated disease manifesting as joint inflammation with functional impairment associated with psoriasis. Recently, PsA has emerged as a systemic disease with several comorbidities, such as cardiovascular diseases and metabolic disorders. Apremilast is a targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) directed against phosphodiesterase 4 (PDE4) with demonstrated efficacy and safety in PsA and psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm8030398DOI Listing

[Prevalence of ten Immune-mediated inflammatory diseases (IMID) in Spain].

Rev Esp Salud Publica 2019 Mar 25;93. Epub 2019 Mar 25.

Medicina Preventiva y Salud Pública, Universidad Rey Juan Carlos, Madrid, Spain.

Objective: Immune-mediated inflammatory diseases (IMID) are chronic and highly disabling diseases that share inflammatory sequences and immunological dysregulations. Considered as a disease in itself, the prevalence of IMID is virtually unknown. The aim of this study was to assess the prevalence of 10 selected UDI, including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, hidradenitis suppurativa, sarcoidosis and uveitis in Spain. Read More

View Article

Download full-text PDF

Source
March 2019
4 Reads